Induction chemotherapy for locally advanced nasopharyngeal carcinoma treated with concurrent chemoradiation: A systematic review and meta-analysis

Prognosis of nasopharyngeal carcinoma with insufficient radical dose to the primary site in the intensity‐modulated radiotherapy era

“…In this study, the prognosis of NPC in children was worse than that in NPC-91-GPOH and NPC-2003-GPOH/DCOG studies. 6 Compared to most malignant tumors, the prognosis of NPC is better and most patients achieve longer term survival. The above studies utilizing reduced-dose radiotherapy were conducted after IC, which can effectively reduce tumor size and increase the dose uniformity in the target area.…”

“…Furthermore, a metaanalysis demonstrated that IC improved both PFS and OS for locally advanced NPC treated with CCRT. 6 Compared to most malignant tumors, the prognosis of NPC is better and most patients achieve longer term survival. 5,20 Radiotherapy is a double-edged sword, which can acquire good therapeutic effects but also leads to serious side effects.…”

“…4,5 In the prevalence area of NPC, induction chemotherapy (IC), which effectively shrinks the volume of the tumor and minimizes the risk of distant metastasis, 6 has become one of the main treatment components, especially in China. 4,5 In the prevalence area of NPC, induction chemotherapy (IC), which effectively shrinks the volume of the tumor and minimizes the risk of distant metastasis, 6 has become one of the main treatment components, especially in China.…”

“…therapy (IMRT) and chemotherapy, the treatment outcomes of NPC have been significantly improved, and the localregional control rate has been reported at up to 90%. 4,5 In the prevalence area of NPC, induction chemotherapy (IC), which effectively shrinks the volume of the tumor and minimizes the risk of distant metastasis, 6 has become one of the main treatment components, especially in China. Recently, a randomized phase III trial showed that TPF (docetaxel, cisplatin, and 5-fluorouracil) IC for NPC can effectively improve overall survival (OS).…”

Less is more: role of additional chemotherapy to concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal cancer management

“…There have been many comparative studies to investigate the roles of the additional IC or AC to RT alone or CCRT Less is more: role of additional chemotherapy to concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal cancer management https://doi.org/10.3857/roj.2019.00311 settings, typically through the phase 3 randomized controlled trial (RCT). And, based on these trials, several important metaanalysis reports have been published recently [1][2][3][4][5][6][7][8][9][10][11]. The most recent guideline by the National Comprehensive Cancer Network (NCCN) on the treatment of stage II-IVb nasopharynx cancer highly recommends the clinical trials, and listed two options of IC + CCRT and CCRT + AC as category 2a, while CCRT alone as category 2b, respectively [12].…”